RESEARCH TRIANGLE PARK, N.C. & San Jose, Calif.--(BUSINESS WIRE)--Feb. 2, 2004--Tecan US, a leader in the Life Sciences supply industry, today introduced Safire2, a fully modular monochromator-based microplate detection system with a full range of high speed fluorescence techniques. Safire2 enables high throughput screening and assay development to be performed on one instrument. Source: Tecan US
· View multimedia news release
Carl Severinghaus, President, Tecan US remarked, “Safire2 was developed to meet the needs of today’s drug discovery laboratories that require speed, sensitivity and flexibility. The industry has been eagerly waiting for a time and cost-saving automation solution like Safire2 that eliminates the need to switch instruments when moving from assay development to high throughput screening.”
With Safire2, detection modules are available for top and bottom fluorescence intensity measurements, fluorescence polarization studies and multi-channel absorbance and luminescence measurements. This microplate detection system has a variety of options to fit application requirements, and will enable researchers to perform the latest biomolecular assays for primary or secondary screening, such as molecular interaction assays, kinase assays, protease assays or highly sensitive G-protein-coupled receptor assays. Another key feature is that consecutive measurements in different fluorescent modes may be made with the shortest possible time interval between measurements.
Safire2 does not require a time-consuming filter change, and all of the wavelengths are easily accessible through a specially designed fast-scanning monochromator. Safire2 is easily combined with a stacker module that allows rapid processing of up to 50 microplates. Through easy integration into Tecan’s Freedom EVO series platforms, users also have access to fully automated drug discovery platforms.
About Tecan
Tecan (www.tecan.com) is a leading player in the Life Sciences supply industry that specializes in the development, production, and distribution of solutions enabling the discovery of pharmaceutical substances, as well as for genomics, proteomics, and diagnostics. Tecan clients are leading pharmaceutical and biotechnology companies, university research departments and diagnostic laboratories. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both North America and Europe and maintains a sales and service network in 52 countries. In 2002, Tecan achieved sales of CH 332.2 million (USD 212.9 million; EUR 226.0 million). Registered shares of Tecan Group are traded on the SWX Swiss Exchange (TK: TECN / Reuters: TECZn.S / Valor : 1210019).
MULTIMEDIA AVAILABLE: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=4562071
Contact:
Tecan US Michele Valenta, 919-361-5200 or Wilder Communications, Inc. Lisa Wilder, 919-349-3357
Source: Tecan US